Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;34(1):155-160.
doi: 10.1038/s41433-019-0669-7. Epub 2019 Nov 26.

Home monitoring for glaucoma

Jemaima Che Hamzah  1 , Qëndresë Daka  2 , Augusto Azuara-Blanco  3
Affiliations
Review

Home monitoring for glaucoma

Jemaima Che Hamzah et al. Eye (Lond). 2020 Jan.

Abstract
in English, Chinese

Glaucoma services are overwhelmed and struggling to accommodate current demand. Reducing the need for hospital based services would improve our ability to see those most at risk of vision loss, which could both reduce demand and improve patient outcomes. Digital technologies that provide opportunities for home monitoring of glaucoma progression have potential to contribute to solve these challenges and, potentially, improve glaucoma care. This article will review the literatures of well-established technologies that support home monitoring for glaucoma, specifically home tonometry (with rebound tonometry) and perimetry with Moorfields Motion Displacement Test and Melbourne Rapid Field.

摘要: 青光眼的医疗服务已不堪重负但仍难满足当前需求, 减少对医院诊疗的需求有利于我们诊治哪些高风险的视力丧失患者, 这既能减少对医疗资源的需求又能改善患者预后。数字技术能在家中监测青光眼的进展, 并且有利于目前所面临的挑战, 以及提高青光眼的护理水平。本文通过检索文献, 对家庭监测青光眼的成熟技术作简要综述, 特别着重强调两种家用仪器: 家用眼压计 (回弹式眼压计) 以及利用Moorfields运动位移测试 (MMDT) 以及墨尔本快速视野检测仪 (MRF) 。.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Icare® HOME tonometer (TA022; Icare Finland Oy)
See this image and copyright information in PMC

References

    1. Bourne RR, Taylor HR, Flaxman SR, Keefe J, Leasher J, Naidoo K, et al. Number of people blind or visually impaired by glaucoma worldwide and in world regions 1990–2010: a meta-analysis. PLoS One. 2016;11:e0162229. doi: 10.1371/journal.pone.0162229. - DOI - PMC - PubMed
    1. Boland MV, Ervin AM, Friedman DS, Jampel HD, Hawkins BS, Vollenweider D, et al. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158:271–9. doi: 10.7326/0003-4819-158-4-201302190-00008. - DOI - PubMed
    1. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13. doi: 10.1001/archopht.120.6.701. - DOI - PubMed
    1. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–79. doi: 10.1001/archopht.120.10.1268. - DOI - PubMed
    1. Investigators TA. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130:429–40. - PubMed